JP4580371B2 - アゴメラチンの新規な結晶形態iv、その製造方法、およびそれを含有する薬学的組成物 - Google Patents
アゴメラチンの新規な結晶形態iv、その製造方法、およびそれを含有する薬学的組成物 Download PDFInfo
- Publication number
- JP4580371B2 JP4580371B2 JP2006211621A JP2006211621A JP4580371B2 JP 4580371 B2 JP4580371 B2 JP 4580371B2 JP 2006211621 A JP2006211621 A JP 2006211621A JP 2006211621 A JP2006211621 A JP 2006211621A JP 4580371 B2 JP4580371 B2 JP 4580371B2
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- disorder
- pharmaceutical composition
- agomelatine
- insomnia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Description
それぞれ、25mgの用量を含有する、1,000錠剤の製造処方:
実施例1の化合物.......................25 g
乳糖一水和物.........................62 g
ステアリン酸マグネシウム................... 1.3g
トウモロコシ澱粉.......................26 g
麦芽デキストリン....................... 9 g
コロイド状無水シリカ..................... 0.3g
A型グリコール酸ナトリウム澱粉................ 4 g
ステアリン酸......................... 2.6g
実施例1の化合物.......................25 g
乳糖一水和物.........................62 g
ステアリン酸マグネシウム................... 1.3g
ポビドン........................... 9 g
コロイド状無水シリカ..................... 0.3g
グリコール酸ナトリウムセルロース...............30 g
ステアリン酸......................... 2.6g
Claims (5)
- 請求項1記載の式(I)の化合物の結晶形態IVを製造する方法であって、アゴメラチンを、融解が完了するまで110℃に加熱し、次いで50〜70℃に急冷し、前記結晶形態IVが晶出するまで5時間、70℃に保つことを特徴とする方法。
- 活性成分として、請求項1記載のアゴメラチンの結晶形態IVを、1種類またはそれ以上の、薬学的に許容され得る担体と組み合わせて含む薬学的組成物。
- メラトニン作用障害の処置のための医薬の製造に用いるための、請求項3記載の薬学的組成物。
- 睡眠障害、ストレス、不安、季節性情動障害または重度うつ病、心血管病理、消化系病理、時差ぼけによる不眠または疲労、精神分裂症、不安発作、憂うつ、食欲障害、肥満、不眠、精神異常、てんかん、糖尿病、パーキンソン病、老人性痴呆、正常または病的加齢に付随する障害、偏頭痛、記憶喪失、アルツハイマー病、脳循環障害、性機能不全、あるいは癌の処置のための医薬の製造に用いるための、請求項3記載の薬学的組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0508277A FR2889522B1 (fr) | 2005-08-03 | 2005-08-03 | Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007051141A JP2007051141A (ja) | 2007-03-01 |
JP4580371B2 true JP4580371B2 (ja) | 2010-11-10 |
Family
ID=36589248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006211621A Expired - Fee Related JP4580371B2 (ja) | 2005-08-03 | 2006-08-03 | アゴメラチンの新規な結晶形態iv、その製造方法、およびそれを含有する薬学的組成物 |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP1752444A1 (ja) |
JP (1) | JP4580371B2 (ja) |
CN (1) | CN100445264C (ja) |
AR (1) | AR057714A1 (ja) |
AU (1) | AU2006203340B2 (ja) |
BR (1) | BRPI0603043A (ja) |
CA (1) | CA2555119A1 (ja) |
CO (1) | CO5780132A1 (ja) |
EA (1) | EA010867B1 (ja) |
FR (1) | FR2889522B1 (ja) |
GE (1) | GEP20094577B (ja) |
GT (1) | GT200600345A (ja) |
HK (1) | HK1098129A1 (ja) |
MA (1) | MA28450B1 (ja) |
MX (1) | MXPA06008693A (ja) |
MY (1) | MY141306A (ja) |
NO (1) | NO20063518L (ja) |
NZ (1) | NZ548863A (ja) |
PE (1) | PE20070242A1 (ja) |
SA (1) | SA06270254B1 (ja) |
SG (1) | SG130111A1 (ja) |
TW (1) | TWI327564B (ja) |
UA (1) | UA83718C2 (ja) |
WO (1) | WO2007015002A2 (ja) |
ZA (1) | ZA200606455B (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2923482B1 (fr) * | 2007-11-09 | 2010-01-29 | Servier Lab | Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
FR2934856B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede d'obtention de la forme cristalline v de l'agomelatine |
CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
WO2011006387A1 (zh) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法 |
CN102001959B (zh) * | 2009-09-01 | 2014-07-02 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
CN102050755B (zh) * | 2009-10-29 | 2014-11-05 | 重庆医药工业研究院有限责任公司 | 阿戈美拉汀的晶型及其制备方法 |
CN101781226B (zh) | 2009-12-23 | 2012-03-28 | 天津泰普药品科技发展有限公司 | 阿戈美拉汀及其药物组合物 |
CN101870662B (zh) * | 2010-05-21 | 2013-03-20 | 中山大学 | 结晶型阿戈美拉汀溶剂化物及其制备方法 |
CL2011001405A1 (es) | 2010-06-10 | 2012-03-30 | Gador S A Conicet | Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina. |
CN102690210A (zh) | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 |
CN102690209A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 |
FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
CN102503886B (zh) * | 2011-10-11 | 2013-09-11 | 中山大学 | 阿戈美拉汀-异烟碱共晶及其组合物和制备方法 |
ES2634243T3 (es) | 2011-11-30 | 2017-09-27 | Ratiopharm Gmbh | Complejo de agomelatina-urea y formas cristalinas del mismo |
CZ2012108A3 (en) | 2012-02-15 | 2013-02-27 | Zentiva Ks | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
CN102643208B (zh) * | 2012-04-14 | 2013-11-06 | 中山大学 | 一种阿戈美拉汀ⅰ晶型的制备方法 |
WO2014096373A1 (en) | 2012-12-21 | 2014-06-26 | Laboratorios Lesvi, S. L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
FR3001894A1 (fr) | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
PT2810656T (pt) | 2013-06-06 | 2017-11-13 | Zentiva As | Formulações de agomelatina compreendendo agomelatina na forma de cocristais |
EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
CZ2013621A3 (cs) | 2013-08-13 | 2015-02-25 | Zentiva, K.S. | Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci |
WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
EP3075724B1 (en) | 2015-03-31 | 2023-07-12 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Solid form of agomelatine |
EP3466413A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Pharmaceutical composition containing agomelatine and process for the preparation thereof |
EP3466923A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Process for the preparation of agomelatine in crystalline form |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0748331A (ja) * | 1990-02-27 | 1995-02-21 | Adir | ナフタレン構造を有する新しい誘導体、その製造方法およびそれを含む薬学的組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
FR2866336B1 (fr) * | 2004-02-13 | 2006-03-24 | Servier Lab | Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine |
-
2005
- 2005-08-03 FR FR0508277A patent/FR2889522B1/fr not_active Expired - Fee Related
-
2006
- 2006-07-19 PE PE2006000867A patent/PE20070242A1/es not_active Application Discontinuation
- 2006-07-24 MA MA29211A patent/MA28450B1/fr unknown
- 2006-07-31 CO CO06074815A patent/CO5780132A1/es not_active Application Discontinuation
- 2006-07-31 GT GT200600345A patent/GT200600345A/es unknown
- 2006-08-01 NZ NZ548863A patent/NZ548863A/en not_active IP Right Cessation
- 2006-08-01 SA SA06270254A patent/SA06270254B1/ar unknown
- 2006-08-01 SG SG200605172-6A patent/SG130111A1/en unknown
- 2006-08-02 TW TW095128301A patent/TWI327564B/zh not_active IP Right Cessation
- 2006-08-02 MX MXPA06008693A patent/MXPA06008693A/es active IP Right Grant
- 2006-08-02 MY MYPI20063734A patent/MY141306A/en unknown
- 2006-08-02 BR BRPI0603043-2A patent/BRPI0603043A/pt not_active Application Discontinuation
- 2006-08-02 EP EP06291252A patent/EP1752444A1/fr not_active Withdrawn
- 2006-08-02 EP EP08017459A patent/EP2008994A1/fr not_active Withdrawn
- 2006-08-02 AR ARP060103365A patent/AR057714A1/es unknown
- 2006-08-02 NO NO20063518A patent/NO20063518L/no not_active Application Discontinuation
- 2006-08-02 GE GEAP20069559A patent/GEP20094577B/en unknown
- 2006-08-02 EA EA200601271A patent/EA010867B1/ru not_active IP Right Cessation
- 2006-08-02 WO PCT/FR2006/001867 patent/WO2007015002A2/fr active Application Filing
- 2006-08-02 UA UAA200608687A patent/UA83718C2/ru unknown
- 2006-08-03 CN CNB2006101083948A patent/CN100445264C/zh not_active Expired - Fee Related
- 2006-08-03 AU AU2006203340A patent/AU2006203340B2/en not_active Ceased
- 2006-08-03 JP JP2006211621A patent/JP4580371B2/ja not_active Expired - Fee Related
- 2006-08-03 CA CA002555119A patent/CA2555119A1/fr not_active Abandoned
- 2006-08-03 ZA ZA200606455A patent/ZA200606455B/xx unknown
-
2007
- 2007-04-30 HK HK07104584.7A patent/HK1098129A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0748331A (ja) * | 1990-02-27 | 1995-02-21 | Adir | ナフタレン構造を有する新しい誘導体、その製造方法およびそれを含む薬学的組成物 |
Also Published As
Publication number | Publication date |
---|---|
HK1098129A1 (en) | 2007-07-13 |
EA200601271A1 (ru) | 2007-02-27 |
EP2008994A1 (fr) | 2008-12-31 |
MY141306A (en) | 2010-04-16 |
MA28450B1 (fr) | 2007-03-01 |
NO20063518L (no) | 2007-02-05 |
CO5780132A1 (es) | 2007-07-31 |
CN100445264C (zh) | 2008-12-24 |
WO2007015002A2 (fr) | 2007-02-08 |
WO2007015002A3 (fr) | 2007-04-12 |
TWI327564B (en) | 2010-07-21 |
GEP20094577B (en) | 2009-01-12 |
CN1907957A (zh) | 2007-02-07 |
SG130111A1 (en) | 2007-03-20 |
MXPA06008693A (es) | 2007-02-02 |
AU2006203340B2 (en) | 2012-07-19 |
FR2889522A1 (fr) | 2007-02-09 |
EP1752444A1 (fr) | 2007-02-14 |
BRPI0603043A (pt) | 2007-03-20 |
NZ548863A (en) | 2008-03-28 |
TW200736198A (en) | 2007-10-01 |
CA2555119A1 (fr) | 2007-02-03 |
ZA200606455B (en) | 2007-12-27 |
FR2889522B1 (fr) | 2007-12-28 |
UA83718C2 (ru) | 2008-08-11 |
GT200600345A (es) | 2007-03-28 |
SA06270254B1 (ar) | 2010-08-02 |
JP2007051141A (ja) | 2007-03-01 |
AU2006203340A1 (en) | 2007-02-22 |
AR057714A1 (es) | 2007-12-12 |
EA010867B1 (ru) | 2008-12-30 |
PE20070242A1 (es) | 2007-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4580371B2 (ja) | アゴメラチンの新規な結晶形態iv、その製造方法、およびそれを含有する薬学的組成物 | |
JP4580370B2 (ja) | アゴメラチンの新規な結晶形態iii、その製造方法、およびそれを含有する薬学的組成物 | |
JP4575337B2 (ja) | アゴメラチンの新規な結晶形態v、その製造方法、およびそれを含有する薬学的組成物 | |
US8067639B2 (en) | Crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
US7358395B2 (en) | Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
US7910625B2 (en) | Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
US7939566B2 (en) | Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
KR100904116B1 (ko) | 아고멜라틴의 ⅴ 결정형, 이의 제조 방법 및 이를 함유하는 약제 조성물 | |
KR20070017020A (ko) | 아고멜라틴의 결정질 형태 ⅳ, 이의 제조 방법 및 이를함유하는 약제 조성물 | |
KR20070017019A (ko) | 아고멜라틴의 결정질 형태 ⅲ, 이의 제조 방법 및 이를함유하는 약제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090929 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100326 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100716 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100817 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100827 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4580371 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |